Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice

Fig. 4

Adherence to anti-TNF therapy according to C-reactive protein (CRP) status at baseline. Kaplan-Meier survival curves from initiation of anti-TNF therapy, showing adherence to anti-TNF treatment in patients with non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) who had CRP elevation (CRP >3.0 mg/l) or did not have CRP elevation (CRP ≤3.0 mg/l) at baseline. Cessation of anti-TNF therapy was defined as stopping therapy, without restarting another anti-TNF agent within 3 months. Numbers of patients still on anti-TNF treatment at the respective time points are shown below the graph

Back to article page